Glaucoma treatment is not always immediate or automatic. The glaucoma treatment decision depends on confirmed diagnosis, risk of progression, and long-term impact, not a single test result. Most people who come to me with a glaucoma diagnosis are not asking for treatment. They are asking something much more basic: “Do I really need to start treatment for glaucoma?”
And often, that question has not been fully answered. Here’s what you need to make your glaucoma treatment decision, explains Dr Bhartiya.
Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.
The uncomfortable truth
Not all glaucoma needs immediate treatment. Not all treatment prevents progression. And not all progression is fast enough to matter in the short term.
But equally: Some patients lose vision quietly while everything appears “stable.”
👉 The difficulty is not diagnosis.
👉 The difficulty is decision-making over time.
What actually determines treatment
Treatment is not based on one number or one test.
It depends on:
- Your age and life horizon
- The structure of your optic nerve
- Functional change over time (not one field test)
- Risk of progression, not just presence of disease
This is where most consultations become oversimplified.
When you should pause before starting treatment
- You’ve had one abnormal test only
- Your scans and fields don’t match
- You have no clear baseline
- The diagnosis was made quickly without longitudinal review
In these cases, a second opinion is not delay, it is risk correction.
When treatment should not be delayed
- Clear structural damage with progression risk
- Repeatable field defects
- Strong family history with early signs
- Younger patients with long disease horizon
Here, waiting creates silent loss.
Understanding Glaucoma
Glaucoma is not a yes/no diagnosis. It is a long-arc risk management problem.
The real question is not: “Do I have glaucoma?”
But: “What happens if we do nothing for the next 5–10 years?”
👉 If that question has not been answered clearly, you are not ready to commit to treatment yet.
Known for her structured approach to glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.
If you’ve been advised treatment but are unsure whether it’s necessary, a structured second opinion can help clarify both diagnosis and long-term risk. Second Opinion Form
❓ FAQs
Do all glaucoma patients need treatment?
No. Some patients need careful observation before starting treatment. The key is assessing risk of progression over time, not just presence of early changes.
Can I wait before starting glaucoma drops?
In selected cases, yes, but only with structured monitoring. Waiting without a plan is risky. Waiting with clear follow-up and baseline comparison can be appropriate.
Are glaucoma eye drops lifelong?
Often, yes. That’s why the decision to start should be made carefully. Starting treatment is easy. Continuing it for years is what affects quality of life.
What happens if I delay treatment?
It depends on your individual risk. Some patients remain stable for years. Others may progress silently. The decision should be based on:
- age
- baseline damage
- rate of change
And not fear alone.
Can glaucoma be treated without drops?
In some cases, laser or surgery may be options. But the real question is not the method, it is whether treatment is needed at all, and when.
Why do different doctors give different opinions?
Because glaucoma is not a binary diagnosis.
It involves interpretation of:
- tests
- patterns
- risk over time
Different doctors may weigh these differently, especially without long-term data.
When should I seek a second opinion?
- Diagnosis made on limited testing
- Conflicting reports
- Uncertainty about starting lifelong treatment
- Progression despite treatment
Read the research articles
This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine. This article was updated in April 2026.
She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.
Access her work on Pubmed, Google Scholar, ResearchGate and ORCID.
Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care
www.drshibalbhartiya.com
+91 88826 38735
1500+ Five Star Patient Reviews Google Business Profile
Upload your reports for a structured review.
If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation for glaucoma